Intellia Therapeutics' stock price has seen significant movement, with reports of both declines and gains. The stock's performance appears to be tied to the company's phase 3 data for lonvo-z and its launch plans, as well as its financial situation, including an equity raise. The direction and magnitude of the stock's movement are unclear, with different reports citing varying percentage changes.